Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease […]

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026

Could a new protein become a future treatment target in pulmonary arterial hypertension(PAH)? Researchers have identified a protein called placental growth factor (PlGF) as a possible new driver of pulmonary arterial hypertension (PAH). Although its name suggests it is only involved in pregnancy, placental growth factor is also active in blood vessels and the immune

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026 Read Post »

The e-book for the May 2026 edition of Transplant International is available online in open access

The e-book for the May 2026 edition of Transplant International is available online in open access at this link The cover features a letter to the editors reporting the impressive summiting of Aconcagua, the highest peak in the Americas, without supplemental oxygen by a lung transplant recipient accompanied by the medico-surgical team from Medical University

The e-book for the May 2026 edition of Transplant International is available online in open access Read Post »

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026

Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026 Read Post »

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026

This “How I Do It” article addresses a practical question now facing pulmonary arterial hypertension (PAH) clinicians: as sotatercept gets added to background combination treatment, some patients on prostacyclin therapy show sustained improvement — raising the question of whether their prostacyclin dose can be safely reduced. The challenge is that standard monitoring tools (functional class,

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026 Read Post »

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026

This single-center retrospective study, conducted at Qilu Hospital, Shandong University (China), from February 2022 to November 2023, set out to compare two strategies for selexipag-based triple combination therapy in patients with pulmonary arterial hypertension (PAH): starting all three drugs together (initial/upfront triple therapy) versus adding selexipag on top of existing dual therapy (early sequential triple

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026 Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026

A 10-week fully remote, home-based exercise programme for people with pulmonary hypertension (pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) was found to be both acceptable and beneficial, according to a study conducted by a group of Irish researchers, based on qualitative interviews with 13 participants. The programme combined aerobic, resistance and respiratory

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026

A cross-sectional Swiss study involving 124 pulmonary arterial hypertension patients across six centres estimated the annual cost at nearly €139,000 per patient, with direct healthcare costs accounting for 78.5% of this figure — driven predominantly by pharmacological treatment, which alone represented 65% of total costs. Indirect costs, including productivity losses and informal care, made up

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026 Read Post »

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026

Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential control arms. The method has

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026 Read Post »

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026

The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on patients’ QoL measured by PROMs.

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026 Read Post »

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant

This month, The Canadian Pulmonary Hypertension Association PHA Canada is raising awareness about the life-changing impact of organ and tissue donation. The newest issue of their magazine Connections is dedicated to Transplant & Pulmonary Hypertension, and it explores this important topic through stories, insights, and resources from the community. 👉 Subscribe to Connections and receive

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant Read Post »

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

TRANSLATE »
Scroll to Top